10-Q: Kraig Biocraft Laboratories Reports Q3 2024 Results, Cites Ongoing Efforts to Scale Spider Silk Production

Kraig Biocraft Laboratories reported no revenue for the third quarter of 2024, with a net loss of $433,200, while continuing to focus on research and development and scaling production of its spider silk technology.

Summary

• Kraig Biocraft Laboratories reported no revenue for the third quarter of 2024, consistent with the same period in 2023.
• The company's net loss for the quarter was $433,200, an improvement from the $549,273 loss in the third quarter of 2023.
• Operating expenses totaled $423,797 for the quarter, compared to $459,445 in the same period last year.
• Research and development expenses decreased to $24,968 from $39,129 year-over-year.
• General and administrative expenses decreased to $205,298 from $224,687 year-over-year.
• Professional fees increased to $40,922 from $23,294 year-over-year.
• The company experienced a net change in unrealized appreciation on investment in gold bullion of $78,420, compared to a depreciation of $17,055 in the prior year.
• Interest expense increased to $132,890 from $121,969 year-over-year.
• For the nine months ended September 30, 2024, the net loss was $2,547,264, compared to $1,705,146 for the same period in 2023.
• The company's cash and cash equivalents were $1,190,027 as of September 30, 2024, down from $2,551,834 at the end of 2023.
• The company has a working capital deficit of $8,102,679 and a stockholders' deficit of $7,357,009.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including no revenue, substantial losses, and a going concern warning. While there are some positive aspects, such as decreased R&D expenses and a net change in unrealized appreciation on investment in gold bullion, the overall sentiment is negative due to the company's precarious financial situation and dependence on future capital raises.

Positives

• The net loss for the third quarter of 2024 decreased compared to the same period in 2023.
• Research and development expenses decreased in the third quarter of 2024 compared to the same period in 2023.
• The company experienced a net change in unrealized appreciation on investment in gold bullion of $78,420, compared to a depreciation of $17,055 in the prior year.

Negatives

• The company reported no revenue for the third quarter of 2024.
• The company has a significant working capital deficit of $8,102,679.
• The company has a stockholders' deficit of $7,357,009.
• The company's cash and cash equivalents decreased to $1,190,027 as of September 30, 2024.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• Professional fees increased by 75.68% in Q3 2024 compared to Q3 2023.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company has a significant working capital deficit and stockholders' deficit.
• The company has not yet achieved revenue from its operations.
• The company's cash resources are insufficient to meet its planned business objectives without additional financing.
• The company's operations are subject to risks inherent in growing an enterprise, including limited capital resources and risks inherent in the research and development process.
• The company's production operations have been impacted by seasonal challenges, climate fluctuations, and the COVID-19 pandemic.

Future Outlook

The company plans to expand research and development, develop a line of fabrics and apparel, expand spider silk production capacity, improve the robustness of its silkworm lines, and pursue collaborative research and commercialization opportunities. The company also plans to actively pursue the development of commercial scale production of its recombinant materials.

Management Comments

• Management believes that new platform technologies will allow the company to outpace and surpass the performance of Dragon Silk.
• Management believes that the company will be able to target metric tons of capacity of its recombinant spider silk fiber per annum from its operations once it overcomes the current challenges and reaches maximum utilization.
• Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Industry Context

The company is operating in the specialty fiber and technical textile industries, which are characterized by high-performance materials used in various applications. The company is using genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in these markets. The company's approach brings biotechnology to the historical silk industry, allowing it to introduce materials with innovative properties.

Comparison to Industry Standards

• The company's lack of revenue is a significant deviation from industry standards for companies that have been operating for as long as Kraig Biocraft Laboratories.
• The company's reliance on private loans and the sale of common stock for funding is not uncommon for early-stage biotech companies, but the magnitude of the losses and the going concern warning are concerning.
• The company's focus on recombinant spider silk is a unique approach compared to traditional textile companies, but it is also a high-risk, high-reward strategy.
• The company's research and development expenses are relatively low compared to other biotech companies, which may be a concern for its ability to innovate and compete.
• The company's operating expenses are high relative to its lack of revenue, which is a common challenge for pre-revenue companies.

Related Party Transactions

• The company has significant related party transactions, including loans from its founder and CEO, royalty agreement payable to the CEO, and accrued salaries and interest owed to senior staff.
• The company recorded $60,693 as an in-kind contribution of interest related to the loan from its founder and CEO during the nine months ended September 30, 2024.
• The company owes $7,086,560 to related parties in accrued salaries and accrued interest as of September 30, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and dependence on future capital raises.
• Employees may be impacted by the company's financial challenges, including potential furloughs or layoffs.
• Customers and suppliers may be impacted by the company's ability to continue operations and fulfill contracts.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to expand its research and development efforts.
• The company plans to develop a line of fabrics and apparel.
• The company plans to continue the expansion of its spider silk production capacity.
• The company plans to improve the robustness of its recombinant spider silk lines.
• The company plans to accelerate its microbiology and selective breeding programs.
• The company plans to consider buying an established revenue-producing company.
• The company plans to pursue collaborative research opportunities.
• The company plans to pursue collaborative commercialization, marketing, and manufacturing opportunities.
• The company plans to actively pursue the development of commercial-scale production of its recombinant materials.

Key Dates

Keywords

spider silk, recombinant DNA, textile, biotechnology, research and development, financial results, going concern, capital raise, silkworms, Vietnam